Images are for illustration purposes only. Packaging may change from time to time and images on our website may or may not be updated.
EpiRepress 60mg tablets for Dogs
Therapeutic indication: Pharmaceuticals: Neurological preparations: Others
Active ingredient: Phenobarbital
Product:EpiRepress 60mg tablets for Dogs
Product index: EpiRepress 60mg tablets for Dogs
Qualitative and quantitative composition Each tablet contains as active substance: Phenobarbital 60 mg
White, round tablets, diameter 7.5 mm, upper side: flat, scored into quadrants, lower side: domed, scored into quadrants. The tablets can be divided into halves or quarters.
Target species Dog
Indications for use, specifying the target species
Prevention of seizures due to generalised epilepsy in dogs.
Do not use in the case of hypersensitivity to the active substance or to any other barbiturates or to any of the excipients. Do not use in animals with severe impaired hepatic function. Do not use in animals with serious renal and/or cardiovascular/respiratory disorders. Do not use in dogs weighing less than 6 kg
Special warnings for each target species
The decision to start antiepileptic drug therapy with phenobarbital should be evaluated for each individual case and depends on number, frequency, duration and severity of seizures in dogs. To achieve successful therapy, administration of tablets should occur at the same time(s) each day, and should be co-ordinated with feeding times in a consistent manner. Withdrawal or transition from other types of antiepileptic therapy should be made gradually to avoid precipitating an increase in the frequency of seizures. Some dogs are free of epileptic seizures during the treatment, but some dogs show only a seizure reduction, and some dogs are considered to be non-responders.
Special precautions for use
Special precautions for use in animals
Caution is recommended in animals with: -impaired hepatic and renal function -hypovolemia, anemia and -cardiac or respiratory dysfunction The chance of hepatotoxic side effects can be diminished or delayed using an effective dose that is as low as possible. Monitoring of hepatic parameters is recommended in case of a prolonged therapy. It is recommended to assess the clinical pathology of the patient 2-3 weeks after start of treatment and afterwards every 4-6 months, e. g. measurement of hepatic enzymes and serum bile acids. It is important to know that the effects of hypoxia etc. do cause increased levels of hepatic enzymes after a seizure. Phenobarbital may increase the activity of serum alkaline phosphatase and transaminases. These may demonstrate non-pathological changes, but could also represent hepatotoxicity. Therefore, in the case of suspected hepatotoxicity, liver function tests are recommended. In stabilised epileptic patients, it is not recommended to switch between phenobarbital formulations. However, if this cannot be avoided then additional caution should be taken.. This includes more frequent plasma concentration sampling to ensure that therapeutic levels are maintained. Monitoring for increased side effects and for hepatic dysfunction should be conducted more regularly until stabilisation is confirmed. Withdrawal of therapy with phenobarbital formulations or transition to or from another type of antiepileptic therapy should be made gradually to avoid precipitating an increase in the frequency of seizures. Special precautions to be taken by the person administering the veterinary medicinal product to animals People with known hypersensitivity to barbiturates should avoid contact with this veterinary medicinal product. Phenobarbital is a teratogen and developmental neurotoxicant and transfers to breast milk. The product should not be administered by pregnant women, women intending to become pregnant or whose pregnancy status is unknown, as well as lactating women. Ingestion of Phenobarbital can cause neurotoxicity which may prove fatal. Take utmost care that children do not come into any contact with the product. Children are particularly at risk of intoxication. To prevent accidental ingestion of tablets, the container should be closed immediately after withdrawing the required number of tablets for one administration. Part tablets should be placed back into the container and used at the next administration, as even part tablets pose a health risk to small children if ingested. The container should be stored in a safe place out of the sight and reach of children. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. If possible, the physician should be informed about the time and amount of ingestion, as this information may help to ensure that appropriate treatment is given. Wash hands after use.
Adverse reactions (frequency and seriousness)
Occasionally at the start of treatment, ataxia, somnolence, listlessness and dizziness may occur. In some cases these effects may persist for the entire duration of treatment. Sedation and ataxia often become significant concerns as serum levels reach the higher end of the therapeutic range. Polyuria, polydipsia and polyphagia may occur at average or higher therapeutically active serum concentrations, but these effects are usually transient and disappear with continued medication. In some animals, a paradoxal hyperexcitability may occur, particularly after first starting therapy. As this hyperexcitability is not linked to overdosage, no reduction of dosage is needed. High plasma concentrations (>35â€‘40 µg/ml) may be associated with hepatotoxicity. Treating dogs with phenobarbital may lower their total thyroxine levels (TT4) or free thyroxine levels (FT4); however this may not be an indication of hypothyroidism. Treatment with thyroid hormone replacement should only be started if there are clinical signs of the disease. Phenobarbital can have deleterious effects on stem cells from bone marrow. Consequences are immunotoxic pancytopenia and/or neutropenia. These reactions disappear after cessation of treatment. Superficial necrolytic dermatitis may occur after administration of phenobarbital. If adverse reactions are severe, the administered dose should be decreased.
Use during pregnancy, lactation or lay
Use only accordingly to the benefit-risk assessment by the responsible veterinarian. Studies in laboratory animals have indicated that phenobarbital has an effect during prenatal growth, in particular causing permanent changes in neurological and sexual development. Neonatal bleeding tendencies have been associated with phenobarbital treatment during pregnancy. In case of pregnancy, the risk that the medication may cause an increase in the number of congenital defects must be weighed up against the risk of suspending treatment during pregnancy. Discontinuation of treatment is not advised, but the dosage should be kept as low as possible. Phenobarbital crosses the placenta and, at high doses, (reversible) withdrawal symptoms cannot be ruled out in newborns. The safety of the veterinary medicinal product has not been proven during pregnancy in dogs.
Use only accordingly to the benefit-risk assessment by the responsible veterinarian. Phenobarbital is excreted in small amounts in breast milk and during nursing pups should be monitored carefully for undesired sedative effects. Weaning early may be an option. If somnolence/sedative effects (that could interfere with suckling) appear in nursing newborns, an artificial suckling method should be chosen. The safety of the veterinary medicinal product has not been proven during lactation in dogs.
Interaction with other medicinal products and other forms of interaction
A therapeutic dose of phenobarbital for antiepileptic therapy can significantly induce plasma protein (such as α1acid glycoprotein, AGP), which bind drugs. Therefore special attention must be paid to the pharmacokinetics and doses of drugs simultaneously administered. The plasmatic concentration of cyclosporine, thyroid hormones and theophylline is decreased in the case of concurrent administration of phenobarbital. The effectiveness of these substances is diminished, too. Concurrent use with potassium bromide increases the risk of pancreatitis. Concurrent use with other drugs having a central depressive can result in an increase of the effect of central depressive drugs. Phenobarbital may enhance the metabolism of, and therefore decrease the effect of, antiepileptics, chloramphenicol, corticosteroids, doxycycline, beta blockers and metronidazole. The reliability of oral contraceptives is lower. Phenobarbital may decrease the blood concentration of griseofulvin by reducing its absorption and/or inducing hepatic microsomal enzymes. The following drugs can decrease the convulsive threshold: quinolones, high doses of β-lactam antibiotic, theophyllin, aminophyllin, cyclosporine and propofol for example). Medications which may alter the seizure threshold should only be used if really necessary and when no safer alternative exists. Use of phenobarbital tablets in conjunction with primidone is not recommended as primidone is predominantly metabolized to Phenobarbital.
Amounts to be administered and administration route
The required dosage will differ to some extent between individuals and with the nature and severity of the disorder.
Only intended for oral administration in dogs.
Amount to be administered
The recommended starting dose is 2.5 mg phenobarbital per kg body weight, administered twice daily. Any adjustments to this dose are best made on the basis of clinical efficacy, blood concentrations and the occurrence of undesired effects. The phenobarbital serum concentration considered to be therapeutically active is between 20â€‘40 μg/ml. Steady state serum concentrations are not reached until 1â€‘2 weeks after treatment is initiated. The full effect of the medication occurs approximately after 2 weeks, and doses should not be increased during this time. The phenobarbital serum concentration may be checked after steady state has been achieved, If it is less than 20 μg/ml and/or seizures are not being controlled, the dosage may be increased by 20 % at a time, with associated monitoring of serum phenobarbital levels. If seizures recur, the dose may be increased to a maximum serum concentration of 40 μg/ml. High plasma concentrations may be associated with hepatotoxicity. The tablets can be divided into halves or quarters to ensure accurate dosing. Epirepress tablets can be quartered by pressing on the flat, scored upper side of the tablet with a finger or thumb. The domed, scored lower side of the tablet should be on a firm surface.
Overdose (symptoms, emergency procedures, antidotes), if necessary
Overdosage may result in coma, severe respiratory and cardiovascular depression, hypotension and shock leading to renal failure and death.
The primary management measures are intensive symptomatic and supportive therapy with particular attention being paid to the maintenance of cardiovascular, respiratory, and renal functions and of the electrolyte balance. Treatment of overdosage can, if necessary, consist of gastric lavage with activated charcoal administration. There is no specific antidote, but central nervous system (CNS) stimulants like Doxapram may stimulate the respiratory centre. Give oxygen support.
The antiepileptic effects of phenobarbital are probably the result of at least two mechanisms, being decreased monosynaptic transmission, which presumably results in reduced neuronal excitability and an increase in the motor cortex's threshold for electrical stimulation.
As a weak acid, phenobarbital is absorbed well from the gastrointestinal tract following oral administration to dogs, although peak plasma concentrations are not achieved until 4-6 hours after administration.
Plasma protein binding of phenobarbital is 45 % and the distribution volume is 0.7 ± 0.15 l/kg. A steady-state serum concentration is achieved 8-15.5 days after treatment is initiated. Phenobarbital is reasonably fat-soluble and crosses the blood-brain barrier slowly. The barbiturate effect therefore develops slowly, but persists for a long period of time. Due to the moderate fat solubility of phenobarbital, redistribution to adipose tissue occurs slowly. Phenobarbital crosses the placental barrier and enters breast milk.
Phenobarbital is converted in the liver into p-hydroxy-phenobarbital, which, due to a lower antiepileptic effect, no longer makes any significant contribution to the activity of phenobarbital. Barbiturates cause enzyme induction and thereby accelerate their own breakdown.
About 25 % of the administered dose is excreted in the urine in unchanged form (elimination half-life: 37-75 hours) and about 75 % is excreted as p-hydroxy-phenobarbital glucuronide and sulphate derivatives and as p-hydroxy-phenobarbital itself. Following daily administration of 5.5 mg phenobarbital per kg bodyweight for 90 days, a lower elimination half-life is observed (from 88.7 ± 19.6 to 47.5 ± 10.7 hours). Under alkaline conditions urinary excretion of phenobarbital is accelerated. There is wide individual variation in the degree of phenobarbital metabolism which is caused by the effect of phenobarbital on microsomal liver enzymes. Variations in elimination half-life are not only seen between animals but also within a single animal.
List of excipients: Cellulose microcrystalline Maize starch Gelatin Lactose monohydrate Stearic acid Silica colloidal anhydrous
Shelf-life of the veterinary medicinal product as packaged for sale: 3 years
Shelf life after first opening the immediate packaging: 3 months
Special precautions for storage
Store in the original container. Divided tablets should also be stored in the original container. Keep the container in the outer carton. This veterinary medicinal product does not require any special temperature storage conditions.
Nature and composition of immediate packaging
Brown glass containers (glass type III) with white child-resistant polyethylene stopper in carton. White polyethylene container with white child-resistant polypropylene screw cap in carton. Pack sizes: 30, 60, 120 tablets Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. This should be in accordance with the Misuse of Drugs Regulations 2001.
Marketing Authorisation Holder (if different from distributor)
Desitin Arzneimittel GmbH Weg beim Jäger 214 22335 Hamburg Germany
Marketing Authorisation Number Vm 14040/4000
Date of the first authorisation or date of renewal January 2016
Date of revision of the text February 2016
Any other information
Schedule 3 Controlled drug
Legal category Legal category: POM-V
All prices include VAT where applicable.
|Ease Of Use|
|Value For Money|
|Absence Of Side Effects|
Only verified purchasers of this product can leave a review.
EpiRepress provides an effective guard against epileptic fits
Customer recommends this product
There are currently no questions for EpiRepress - be the first to ask one!